• Arcutis Biotherapeutics enrolled the first participant in its Phase 3 INTEGUMENT-3 trial of Zoryve cream for moderate to severe atopic dermatitis.
• The study will evaluate once-daily roflumilast cream 0.3% in patients ages 6 and older; results have not yet been presented.
• The trial aims to expand Zoryve’s use beyond mild to moderate atopic dermatitis by assessing efficacy, safety and tolerability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcutis Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050800PRIMZONEFULLFEED9870684) on November 05, 2026, and is solely responsible for the information contained therein.